That thought certainly crossed my mind. I would be shocked if Dr. Sonis was not also up to speed on everything K. As it stands Leo has not stated that we are going after any oral cancers, but I'd really like to think that with Dr. Sonis on board some pre-clinicals on mouth and throat cancer lines will be highly likely to be initiated.
Also the other thing I was thinking about is that Dr. Sonis clearly has a lot of genuine interest in B-OM not even taking into account that he "helped research its oral rinse formulation and application prior to Cellceutix's acquisition of the compound in 2013". I say this because of the fact the trial did not end up having Dana Farber as a clinical site. That means he has been actively keeping up with Leo and CTIX and following the trial progress at the other locations because he is likely expecting good results. In my mind, this is just another one of those soft metrics that keeps pointing to the direction of success for CTIX B-OM and all of the B related compounds.